quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 28, 2026

ServiceNow and Anthropic partner to help customers build AI-powered applications, accelerate time to value, and apply trusted AI to critical industries

View original at finance.yahoo.com
ServiceNow and Anthropic partner to help customers build AI-powered applications, accelerate time to value, and apply trusted AI to critical industries Claude is the default model powering ServiceNow Build Agent, helping developers of all skill levels to build and deploy agentic workflows that can reason, act, and exec…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • With ServiceNow AI Platform, claims authorization could be reduced from days to hours while also decreasing costs

    80% confidence
  • ServiceNow is targeting a 50% reduction in time to implement for customers from initial sales conversations through autonomous deployment

    80% confidence
  • A common error enterprises make with AI is to treat it as a kind of 'bolt on' tool that you access now and then. But the way to get much better results is to make AI an integral part of how you get work done — woven into the whole range of things workers do every day. That's where you actually start to see what these systems can do, and it's what we're doing in our partnership with ServiceNow.

    80% confidence
  • Early results show up to 95% reduction in preparation time for sales preparation using Claude

    80% confidence
  • Build Agent early traction has been strong and is expected to quadruple over the next 12 months

    80% confidence
  • ServiceNow with Anthropic is turning intelligence into action through AI-native workflows for the world's largest enterprises. This partnership is about reimagining how work gets done. It puts the power to build, deploy, and scale mission-critical applications into the hands of every person, in every industry, at every level. Together, we are proving that deeply integrated platforms with an open ecosystem are how the future is built.

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,986
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,986 factos verificados com a fonte5,362 documentos-fonte arquivados
Consulte estes dados → isubstrate.com